# RELYVRIO
> **NDA216660** · New Drug Application · Sponsor: AMYLYX · Approved 2022-09-29
## Drug
- **FDA Application Number:** NDA216660
- **Application type:** New Drug Application
- **Brand name:** RELYVRIO
- **Generic name:** Sodium Phenylbutyrate
- **Active ingredients:** SODIUM PHENYLBUTYRATE; TAURURSODIOL
- **Dosage form:** FOR SUSPENSION
- **Route:** ORAL
- **Marketing status:** Discontinued
- **Sponsor:** AMYLYX
- **First approval:** 2022-09-29
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216660)
---
*AI Analytics · CC0 1.0*